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PSA (prostate-speciﬁc antigen) is one of the most widely used proteins for the diagnosis of breast and
prostate cancer. Of note, PSA displays enzymatic activity for the speciﬁc peptide sequence HSSKLQ, which
it recognizes and cleaves. In this study, we developed a site-speciﬁc enzymatic-cleavage-reaction-based
biosensor for the detection of PSA using ﬂuorescein isothiocyanate (FITC)/peptide-conjugated gold (Au)
nanoparticle complexes (FPANs). The FPANs do not initially ﬂuoresce in the spectral region associated
with the ﬂuorophore, due to the quenching effect of the Au nanoparticles. When PSA was added to a
solution containing the FPANs, PSA recognized and cleaved the speciﬁc sequence of the peptides attached
to the Au nanoparticles. As a result, FITCs were separated from the Au nanoparticles and emitted strong
ﬂuorescence in their spectral region. Using this detection method, PSA was successfully detected as a
function of concentration (10 pM—100 nM). This approach is superior to the immunoassay with respect
to the performance of sensor, which is very rapid, simple, and one-step method for the detection of PSA
and other protein markers can be measured for the early detection of several diseases.
& 2013 The Author. Published by Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Prostate-speciﬁc antigen (PSA) is the best serum marker
currently available for the detection of prostate and breast cancer
(Healy et al., 2007). Most current assays for PSA detection are
processed by large analyzers at dedicated testing site, a procedure
that requires samples to be sent away for testing. Conventional
immunoassay methods, including the enzyme-linked immunosor-
bent assay (ELISA) (Voller et al., 1978; Yates et al., 1999), radio-
immunoassay (Goldsmith, 1975; Teppo and Maury, 1987),
chemiluminescence assay (Matsuya et al., 2003; Cesaro-Tadic
et al., 2004), and electrochemical immunoassay (Du et al., 2010;
Ahirwal and Mitra, 2010), all allow for reliable detection. These
immunoassay methods can be sensitive and selective for the
detection of PSA but there are some drawbacks to these
approaches including time-commitment, sustained stability, expo-
sure of active sites for antigen binding, and the fact that anti-
bodies, as proteins, can easily denature with temperature changes.
In the case of ELISA, a sandwich structure must be used to measureB.V.
2-2-717-7008.
Open access under CC BY-NC-NDthe concentration of a disease marker, so at least two antibodies
must bind at each speciﬁc site, and repeated washing steps may
wash away antibodies and reduce detection rates. Moreover,
advanced skills on the part of the user are required due to several
complicated steps of ELISA and the use of diverse analysis equip-
ment. Thus, there is a need to develop PSA-sensing systems that
are more stable, rapid, and simple than the immunoassay methods
in order to develop a point-of-care testing (POCT) system.
Recently, biosensors that use a sequence-speciﬁc peptide
decomposition reaction has been suggested as an alternative to
existing immunoassay-based biosensors. This method has been
used to detect some speciﬁc proteins — i.e., proteases — that
enzymatically cleave speciﬁc peptide bonds. Proteases have been
of particular interest as disease-relevant biomarkers because they
are involved in several important human diseases, including
cancer. Typical examples of proteases include matrix metallopro-
teinases (MMPs), caspases and thrombin (Overall and Kleifeld,
2006; Concha and Abdel-Meguid, 2002). For example, a biosensor
for the detection of MMP-2 has been developed using an induced
peptide-cleavage reaction through the enzymatic property of
MMP-2. In addition, the development of MMP assays using
nanoparticles and unique peptide sequences has been examined
due to the cleavage ability of the peptides and their potential for
use as cancer prognostic markers (Kim et al., 2008; Xia et al.,
2008). For that reason, the development of novel protease assays
with high selectivity and sensitivity is of great signiﬁcance for the license.
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apeutic agents.
In particular, the biological function of PSA involves the enzy-
matic cleavage of a speciﬁc peptide sequence in serum ﬂuid, so
this activity can be exploited to develop a novel assay for PSA
detection that could be more simple and stable than conventional
immunoassay systems—the novel assay need not be concerned
with the stability of or complications arising from antigen—
antibody binding. So far, aside from the aforementioned MMP-
sensing systems, little has been done in this direction for PSA and
other biomarker. Therefore, we developed a novel PSA biosensor
that consists of Au nanoparticles and a speciﬁc peptide sequence
(HSSKLQ) that is recognized and cleaved by PSA (Denmeade et al.,
1997). An enhanced sensitivity for PSA detection was achieved
using this detection method and the process was much simpler
than available immunoassay systems.2. Experimental methods
2.1. Materials and reagents
Au nanoparticles with a diameter of 60 nm were purchased
from BBInternational (Cardiff, UK) and PSA was purchased from
Sigma-Aldrich (St Louis, MO. USA). The speciﬁc peptide sequence
with an attached ﬂuorescein moiety (N′-CCCCCCGLAibAAGGHS-
SLKQGK-FITC-C′) was synthesized by Peptron Inc. (Daejeon,
Korea). Phosphate buffered saline (PBS; pH 7.4, 15 mM) solution
was purchased from Sigma-Aldrich (St. Louis, MO, USA). Each of
these solutions had a pH of 7.4 to mimic physiological pH.
Deionized (DI) water, obtained from a Millipore water system,
was used throughout the experiments. All other chemicals were
analytical grade reagents.
2.2. Au-nanoparticle complex preparation
To prepare the Au nanoparticles (AuNPs), 1 ml of an aqueous
suspension of colloidal AuNPs (diameter 60 nm, 2.61010 per ml)
was centrifuged for 5 min at 10,000 rpm, and the supernatant was
removed. The particles were resuspended in a 0.15 M PBS solution
at pH 7.4, and C-terminal ﬂuorescein isothiocyanate (FITC)-func-
tionalized polypeptides (N′-CCCCCCGLAibAAGGHSSLKQGK-FITC-C′,
82.32 mmol/ml) were added to the solution. The solution was
incubated on a rocking shaker for 3 h to allow the polypeptide
to bind with the AuNP surface through an Au-thiol interaction.
2.3. Conﬁrmation of peptide attachment to AuNPs
The AuNP complexes were attached to the FITC-tailed peptides
to generate our novel PSA biosensor, the FITC/peptide-conjugated
Au-nanoparticle (FPAN) complexes. To conﬁrm binding, the absor-
bance value at 562 nm of the complex was measured and
compared to the value of the peptide in the supernatant using
the BCA (bicinchoninic acid) assay (BCA assay kit, Pierce) and a
UV—vis spectrophotometer (Jasco, V530) after centrifugation for
10 min at 13,200 rpm. In addition, the UV spectra of the AuNP,
FITC, and FPAN in the solution were measured to assess peptide
binding to the AuNPs based on the red-shift of the absorbance
peak compared with the original peak of the AuNPs alone.
2.4. Measurement of PSA concentration using an enzyme cleavage
reaction
The FPANs do not ﬂuoresce in the spectral region associated
with the FITC due to the quenching effect of the AuNPs. When PSA
is added to a solution containing the FPANs, PSAwill recognize andcleave the speciﬁc sequence of the peptides attached to the AuNP
surface. As a result, FITC would be separated from the AuNPs and a
strong ﬂuorescent signal proportional to the PSA concentration
would be observed in the appropriate spectral region. To cause this
reaction, constant concentration of PSA was added to the FPANs
solution, and allowed to react for 60 min. After the enzyme
reaction was complete, AuNPs were spun down and the separated
ﬂuorophores present in the supernatant were analyzed using a
ﬂuorescence spectrophotometer (High Performance Fluorescence
Spectrophotometer Hitachi Model F-7000) at 521 nm.3. Results and discussion
3.1. Characterization of the peptide-modiﬁed AuNP complex
A nanoscale sensor system for PSA detection was developed
using 60 nm colloid AuNP complexes containing small peptide
sequence-ﬂuorophore (FITC) fragments. As a ﬁrst step, the con-
formation of the FPAN was assessed using the UV absorbance
value at 562 nm. The BCA assay, which is a colorimetric assay, was
used to measure the peptide concentration (Fig. 1(a)). In the BCA
method, proteins induce the reduction of Cu (II) cations to Cu (I),
and then bicinchoninic acid is added and the resultant colori-
metric change was assessed. The peptide concentration in the
AuNP solution (2.61010 per ml) was 100 mmol/ml, and its
absorbance value at 562 nmwas 0.32. The peptide concentration
in the supernatant after attachment to the AuNP surface was lower
(0.13) than before the reaction due to the attachment to the
AuNP surface. The number of peptides attached to the AuNPs can
be inferred as proportional to the difference (0.19) between pre-
and post-attachment absorbance values. These results clearly
indicate successful peptide attachment to the AuNPs.
In addition, it is possible to conﬁrm the conjunction of peptide-
AuNP complex directly. Fig. 1(b) shows the UV/vis absorbance
spectrum for each nanomaterial (AuNPs, FITC, and FPANs), which
can also be used to evaluate binding to the AuNPs. AuNPs alone
had a singular absorbance peak at 530 nm, which was shifted to
the right after the biomaterials were attached to the surface of the
nanomaterials due to the LSPR (localized surface plasmon reso-
nance) effect (Delﬁno and Cannistraro, 2009; Li et al., 2010). The
red-shift of the absorption spectra for the peptide-AuNP complex
depended on nanoparticle size, particle aggregation, and local
dielectric environments, which affect the surface plasmon reso-
nance phenomena. This absorbance method was deemed suitable
for directly identifying binding events between the peptide and
nanoparticles. As shown in Fig. 1(b), the absorbance peak for the
AuNPs alone was at 535 nm, while the peak for the AuNP complex
was shifted to the right by 10 nm. Therefore, conjunction of the
peptide to the AuNPs was independently demonstrated by indirect
and direct methods.
3.2. Determination of an efﬁcient amount of peptide for binding to
the AuNP surface
For the purpose of an efﬁcient PSA sensor, it is essential to
compare the ﬂuorescence signals of FPANs in the presence or
absence of PSA in order to determine a suitable peptide concen-
tration on the AuNP surface. As shown in Fig. 1(c), the lowest and
highest peptide concentrations tested (10.4 and 164.64 mmol/ml,
respectively) in AuNP solution both resulted in a low positive-to-
negative ratio (100 nm PSA/non-PSA), corresponding to the attach-
ment of too few peptides for PSA cleavage to efﬁciently occur, or
too many peptides, which may cause steric hindrance, respec-
tively. More speciﬁcally, when the amount of peptide on the AuNP
surface is too low, enzymatic cleavage by PSA is low due to the
Fig. 1. Conﬁrmation of successful conjugation of the peptides to the AuNPs. (a) UV
absorbance change before and after constructing the FPANs. The ﬁrst graph is the
peptide absorbance value at 562 nm measured using the BCA protein assay. After
their attachment to the AuNPs, the absorbance value of the peptides in the
supernatant decreased due to their conjugation to the AuNPs. (b) UV—vis spectrum
of AuNPs and FPANs. AuNPs had a sharp absorbance peak at 535 nm, and the
absorbance peak of the FPAN after the reaction was red-shifted. (c) Assessment of
the FPAN probe at different peptide-FITC concentrations. The positive-to-negative
(P/N) ratio was determined from the activity in the presence and absence of PSA
(100 nM each). The peptide-FITC produced the best signal ratio at a concentration
of 82.32 mmol.
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the other hand, when large quantities of peptide are used, the
space for the peptide-PSA reaction is insufﬁcient because the
peptide-FITC molecules are densely packed on the AuNP surface,i.e. steric hindrance. Therefore, an appropriate peptide quantity
proportional to AuNP concentration is needed to develop the most
effective sensing system. Through these experiments, we obtained
an effective peptide concentration (82.32 mmol/ml) for efﬁcient
PSA detection.
3.3. PSA sensor using an enzyme cleavage reaction
Detection of PSA through enzymatic cleavage was accom-
plished using FPANs consisting of an AuNP and attached
FITC-tailed polypeptides. This approach was very simple and
required only reacting the AuNPs (60 nm) with the polypeptide
complexes (N′-CCCCCCGLAibAAGGHSSLKQGK-FITC-C′) in a 1.5-ml
tube (Fig. 2). The peptide sequence was selected to play four
separate roles in the sensing system (inset). First, the six-cysteine
group was used to attach the polypeptide to the AuNP surface so
that the quenching effect of the AuNP would prevent the ﬂuor-
escent signal from FITC from being emitted. AuNPs are known to
have a superior quenching efﬁciency over a broad range of
wavelengths compared with other organic quenchers. Second,
Aib (α-isobutyric acid) maintained the rigidity of the peptide,
which was important for the third role: the enzymatic cleavage
reaction of the peptide sequence (HSSKLQ) by PSA. Forth, the FITC
ﬂuorophore was used to emit a ﬂuorescent signal following the
loss of quenching after peptide cleavage.
The simple process used to construct the FPAN probe in this
study is superior to other sensing systems because it reduces the
possibility for probe defects in the sensing process and it can be
easily scaled-up for commercialization. The FITC molecules that
are attached to the AuNPs through the polypeptide are quenched
by the AuNPs, so that intact FPAN does not emit a ﬂuorescence
signal. When PSA was added to these suspended FPANs, they
recognized and cleaved the peptide sequence (HSSKLQ), resulting
in the release of the FITC molecules from the AuNPs, which
produces an increase in green ﬂuorescent light. In other words,
the PSA protein un-quenches the ﬂuorescent signal of the FITC
molecules due to the enzymatic activity of PSA.
Through these experiments, we observed a linear relationship
between ﬂuorescence intensity and PSA concentration. The linear
relationship with concentration of PSA and ﬂuorescence signal
intensity is very important in order to ﬁnd out the concentration
of PSA through the ﬂuorescence signal in unknown sample by
using the sensor. In details, if ﬂuorescence signal is proportional to
the concentration, it is possible to make the calibration curve
through its relationship. The created calibration curve is available
to ﬁnd PSA concentration in random samples conversely. By using
our sensing system, it is possible to diagnose prostate cancer
through the measurement of ﬂuorescence signal.
The advantage of the peptide-based PSA assay as compared
with conventional methods, such as immune-based sensing sys-
tems, is that this system is not liable to cause protein denaturation
that would result in a loss of the capture function of the target
molecules. In addition, this system is less difﬁcult than the
heterogeneous microarray approach, where an expensive capture
antibody is ﬁxed at very high concentrations. This biosensor-based
method requires only one step for PSA sensing, whereas sandwich
ELISA requires several steps: i.e., antigen isolation, antibody
ﬁxation, antigen—antibody reaction, detection probe immobiliza-
tion, etc. Moreover, particle separation is simple and fast, and
offers a degree of detection simplicity even when only a few
targets can be identiﬁed in a test sample. Finally, although FITC
was used as the optical probe, other types of probes could be
applied to this system, thus allowing for detection methods other
than ﬂuorescence. These include quantum dots, radioactive
groups, catalytic groups, electrically generated groups, Raman-
active groups, and redox-active groups. In principle, the detectable
Fig. 3. Fluorescence intensity of the novel PSA sensor system in PBS (a) and in
human serum (b). The excitation and emission wavelengths were 490 nm and
521 nm, respectively. Based on this data, the detection limit was found to be 10 pM
of peptide. PSA cleaved the speciﬁc peptide sequence, resulting in an increase in the
emitted ﬂuorescence signal at 521 nm.
Fig. 2. Schematic illustration of the novel PSA sensor system, which utilized FPANs containing a speciﬁc peptide with FITC as a signal generator. The peptide contained six
cysteine residue that was used to conjugate the peptide to the AuNP surface, an Aib (α-isobutyric acid) residue that maintained peptide rigidity, and a PSA cleavage site. PSA
cleaved the speciﬁc peptide sequence to release it from the AuNP surface, which resulted in the generation of a ﬂuorescence signal at 521 nm.
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measurable chemical or physical signature. The limit of detection
and the dynamic range of our sensing system are shown in Fig. 3
for PSA in PBS and human serum. This nanoprobe-based assay
system produces a proportional curve according to PSA concentra-
tion from 10 pM to 100 nM. In details, it can be measured from
pico-molar to nano-molar concentration of PSA, ﬁve magnitude
range with linear relationship and its correlation coefﬁcient is
about 0.98 (R2). Fig. 3 shows a linear relationship between the
ﬂuorescence intensity and the PSA concentration under PBS and
human serum conditions. As exhibited in Fig. 2, upon increasing
the concentration of PSA, the value of the ﬂuorescence intensity
increased. Importantly, this sensing system has several advantages
for diagnostic applications compared with other PSA sensors
including: its dynamic range, which includes the clinical range of
PSA (about 4—10 ng/ml, corresponding to 122—637 pM)
(Kupelian et al., 1996); higher stability than immunosensors, due
to the increased stability of the polypeptide chain relative to
proteins or antibodies; and, simple and rapid detection, which
can be achieved within 1 h, a signiﬁcant reduction over conven-
tional immunoassays without loss of sensitivity and selectivity.4. Conclusion
In summary, PSA, which is a diagnostic marker of prostate cancer,
was rapidly detected using a novel nanocomplex composed of
AuNPs and polypeptides within an hour. This approach provides
the framework for the development of new sensors that are based
on detecting proteins that have enzymatic cleavage activities. It is
superior to other PSA sensors with respect to rapid and simple
detection, which originates from the enzymatic reactivity of the
target protein. In addition, this system can measure over a dynamic
concentration range (10 pM—100 nM), which was within the range
required for clinical detection. We propose that this kind of approach
is simpler, faster, and more cost-effective than conventional
J.H. Choi et al. / Biosensors and Bioelectronics 49 (2013) 415–419 419immunoassay approaches, and that it can be modiﬁed for the
detection of any target that displays enzymatic cleavage activity.Acknowledgment
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